Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$18.32
-1.0%		$16.23
$7.66
▼
$19.26
$5.84B1.261.76 million shs2.01 million shs
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$53.36
-3.1%		$57.73
$11.40
▼
$72.36
$1.58B0.68757,606 shs451,354 shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$74.34
-4.9%		$59.04
$29.90
▼
$82.94
$5.72B0.07742,638 shs1.03 million shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$47.29
-3.5%		$50.11
$27.07
▼
$58.49
$5.67B0.671.02 million shs786,740 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
-0.97%+2.23%+7.96%+42.79%+127.01%
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-3.05%-1.46%-18.45%-20.07%+113.61%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
-4.94%+18.30%+18.23%+34.50%+147.31%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-3.47%-0.80%-10.50%+1.98%+25.01%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$18.32
-1.0%		$16.23
$7.66
▼
$19.26
$5.84B1.261.76 million shs2.01 million shs
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$53.36
-3.1%		$57.73
$11.40
▼
$72.36
$1.58B0.68757,606 shs451,354 shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$74.34
-4.9%		$59.04
$29.90
▼
$82.94
$5.72B0.07742,638 shs1.03 million shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$47.29
-3.5%		$50.11
$27.07
▼
$58.49
$5.67B0.671.02 million shs786,740 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
-0.97%+2.23%+7.96%+42.79%+127.01%
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-3.05%-1.46%-18.45%-20.07%+113.61%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
-4.94%+18.30%+18.23%+34.50%+147.31%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-3.47%-0.80%-10.50%+1.98%+25.01%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
2.88
Moderate Buy$17.33-5.39% Downside
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.67
Moderate Buy$82.0053.67% Upside
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
2.90
Moderate Buy$87.3817.53% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.12
Buy$56.2118.87% Upside

Current Analyst Ratings Breakdown

Latest ANAB, KNSA, AMRX, and SRRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/31/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$21.00
7/30/2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/30/2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$75.00 ➝ $90.00
7/29/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
7/29/2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
7/29/2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$72.00 ➝ $107.00
7/29/2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$64.00 ➝ $98.00
7/29/2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$72.00 ➝ $99.00
7/29/2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$60.00 ➝ $100.00
7/23/2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$60.00 ➝ $75.00
7/21/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$58.00
(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$3.02B1.94$1.56 per share11.73$0.10 per share183.20
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$234.60M6.73N/AN/A$1.34 per share39.82
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$677.56M8.44$0.79 per share93.66$8.50 per share8.75
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/A$2.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$72.06M$0.3821.3017.62N/A5.05%-584.46%7.78%N/A
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$13.23M-$1.08N/A16.42N/A-11.53%N/A-7.75%8/5/2026 (Estimated)
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$59.01M$0.9776.6435.74N/A9.59%13.65%10.09%N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$377.94M-$3.59N/AN/AN/AN/A-163.52%-96.67%8/6/2026 (Confirmed)

Latest ANAB, KNSA, AMRX, and SRRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.8405N/AN/AN/A$3.33 millionN/A
8/5/2026Q2 2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$0.1252N/AN/AN/A$17.33 millionN/A
7/28/2026Q2 2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.2995$0.30+$0.0005$0.30$226.49 million$243.60 million
5/12/2026Q1 2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$0.6436-$1.84-$1.1965-$1.84$18.86 million$25.56 million
5/7/2026Q1 2026 & M&A announcement
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
N/A$0.27N/A$0.19N/A$722.52 million
5/7/2026Q1 2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.82-$0.83-$0.01-$0.83$5.00 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
N/AN/AN/AN/AN/A
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
77.65
2.20
1.59
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
7.58
7.58
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/A
3.90
3.33
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.71
8.64
8.64

Institutional Ownership

CompanyInstitutional Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
31.82%
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
53.95%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%

Insider Ownership

CompanyInsider Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
17.30%
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
31.50%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
51.98%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
10.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
8,500319.02 million263.83 millionOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10029.61 million20.28 millionOptionable
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
22076.94 million36.95 millionOptionable
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
140119.83 million107.49 millionOptionable

Recent News About These Companies

Scholar Rock Holding Corporation $SRRK Shares Bought by Janus Henderson Group PLC
August 1 at 6:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-scholar-rock-holding-corporation-srrk-shares-bought-by-janus-henderson-group-plc-2026-08-01/
Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference
July 30 at 3:15 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scholar-rock-present-canaccord-genuity-120000697.html
Scholar Rock Holding (SRRK) Pulls Back Following A Strong Run, Is It Trading At A Discount?
July 30 at 3:15 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/scholar-rock-holding-srrk-pulls-060757594.html
Scholar Rock (SRRK) Projected to Announce Quarterly Earnings on Thursday
July 30 at 2:25 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/scholar-rock-srrk-projected-to-announce-quarterly-earnings-on-thursday-2026-07-30/
Scholar Rock Holding Corporation $SRRK Shares Purchased by Redmile Group LLC
July 29 at 5:51 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-scholar-rock-holding-corporation-srrk-shares-purchased-by-redmile-group-llc-2026-07-29/
ADAR1 Capital Management LLC Grows Stake in Scholar Rock Holding Corporation $SRRK
July 29 at 3:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-adar1-capital-management-llc-grows-stake-in-scholar-rock-holding-corporation-srrk-2026-07-29/
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
July 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-scholar-rock-holding-corp-to-contact-law-firm-302837031.html
Scholar Rock Holding Corporation $SRRK Shares Bought by Eagle Health Investments LP
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-scholar-rock-holding-corporation-srrk-shares-bought-by-eagle-health-investments-lp-2026-07-28/
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Rating of "Buy" from Analysts
July 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30921628
Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Average Recommendation of "Buy" by Brokerages
July 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/scholar-rock-holding-corporation-nasdaqsrrk-given-average-recommendation-of-buy-by-brokerages-2026-07-26/
D.A. Davidson & CO. Purchases New Position in Scholar Rock Holding Corporation $SRRK
July 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-da-davidson-co-purchases-new-position-in-scholar-rock-holding-corporation-srrk-2026-07-23/
Wedbush Reaffirms Outperform Rating for Scholar Rock (NASDAQ:SRRK)
July 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30915378
Scholar Rock (NASDAQ:SRRK) Receives Outperform Rating from Wedbush
July 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/scholar-rock-nasdaqsrrk-receives-outperform-rating-from-wedbush-2026-07-21/
Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal ...
July 20, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/scholar-rock-provides-timing-committee-120000546.html
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
July 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/20/3330104/0/en/kuehn-law-encourages-investors-of-scholar-rock-holding-corp-to-contact-law-firm.html
Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026
July 20, 2026  |  reuters.comhttps://www.reuters.com/legal/litigation/scholar-rock-says-eu-opinion-sma-drug-may-be-pushed-later-2026-2026-07-20/
Jennison Associates LLC Buys 545,304 Shares of Scholar Rock Holding Corporation $SRRK
July 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jennison-associates-llc-buys-545304-shares-of-scholar-rock-holding-corporation-srrk-2026-07-19/
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
July 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scholar-rock-report-second-quarter-120000910.html
Scholar Rock Holding Corporation $SRRK Holdings Raised by Candriam S.C.A.
July 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-scholar-rock-holding-corporation-srrk-holdings-raised-by-candriam-sca-2026-07-13/
SG Americas Securities LLC Cuts Stake in Scholar Rock Holding Corporation $SRRK
July 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-sg-americas-securities-llc-cuts-stake-in-scholar-rock-holding-corporation-srrk-2026-07-09/
Michael Gilman Sells 2,544 Shares of Scholar Rock (NASDAQ:SRRK) Stock
July 7, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-srrk-insider-buying-and-selling-2026-07-07/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amneal Pharmaceuticals stock logo

Amneal Pharmaceuticals NASDAQ:AMRX

$18.32 -0.18 (-0.97%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$18.19 -0.13 (-0.69%)
As of 07/31/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$53.36 -1.68 (-3.05%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$53.24 -0.12 (-0.22%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Kiniksa Pharmaceuticals International stock logo

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$74.34 -3.86 (-4.94%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$76.03 +1.69 (+2.27%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$47.29 -1.70 (-3.47%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$47.30 +0.01 (+0.01%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas